PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read about their systemic review of PAH medications here.
top of page
Recent Posts
Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The...
In a study of data from the Pulmonary Hypertension Association Registry in the US, researchers looked at who was more likely to skip...
A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an...
bottom of page
Comments